UTHR United Therapeutics Corporation

77.26
+1.2  (+2%)
Previous Close 76.06
Open 76.48
Price To Book 1.46
Market Cap 3,384,831,293
Shares 43,810,915
Volume 906,520
Short Ratio
Av. Daily Volume 817,762

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Tyvaso - INCREASE
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (WHO Group 3)
Phase 3 data released April 8, 2019 did not meet primary endpoint.
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Orenitram
Pulmonary arterial hypertension (PAH)
Refusal to file Letter (RTF) issued August 31, 2017. NDA to be resubmitted 1H 2019.
Trevyent
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 3 portion of trial continues to enroll - noted February 21, 2018.
Unituxin - DISTINCT
Small cell lung cancer

Latest News

  1. Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
  2. Have Insiders Been Selling United Therapeutics Corporation (NASDAQ:UTHR) Shares?
  3. Here’s What Hedge Funds Think About United Therapeutics Corporation (UTHR)
  4. Impact on Jacksonville of mega-merger of United Technologies and Raytheon is uncertain
  5. See what the IHS Markit Score report has to say about United Therapeutics Corp.
  6. United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference
  7. United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference
  8. The Catalyst: Creating Innovation in Health Care - United Therapeutics' Martine Rothblatt at Healthy Returns
  9. Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
  10. Before You Buy United Therapeutics Corporation (NASDAQ:UTHR), Consider Its Volatility
  11. MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript
  12. Edited Transcript of UTHR earnings conference call or presentation 1-May-19 1:00pm GMT
  13. United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin®
  14. United Therapeutics zeroes in on new business lines in wake of generic competition
  15. United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
  16. United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates
  17. United Therapeutics Corporation (UTHR) Q1 2019 Earnings Call Transcript
  18. United Therapeutics: 1Q Earnings Snapshot
  19. United Therapeutics Corporation Reports First Quarter 2019 Financial Results